GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Frontage Holdings Corp (HKSE:01521) » Definitions » Valuation Rank

Frontage Holdings (HKSE:01521) Valuation Rank


View and export this data going back to 2019. Start your Free Trial

What is Frontage Holdings Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Frontage Holdings Valuation Rank Related Terms

Thank you for viewing the detailed overview of Frontage Holdings's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Frontage Holdings (HKSE:01521) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Frontage Holdings Corp (HKSE:01521) » Definitions » Valuation Rank
Comparable Companies
HKSE:02257 HKSE:01167 HKSE:01477 HKSE:02179 HKSE:02616 HKSE:01244 HKSE:01873 HKSE:06622 HKSE:02171 HKSE:02496 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
FGHQF:USA
Address
700 Pennsylvania Drive, Exton, PA, USA, 19341
Website
https://www.frontagelab.com
Frontage Holdings Corp is a contract research organization providing integrated, scientifically driven research, analytical and development services. Geographically the group operates in both PRC and North America. The services provided in the North American segment, include Bioanalytical, CMC, DMPK and Safety and Toxicology services in the USA and Canada. The service offered in PRC includes Bioanalytical, Bioequivalence and CMC services in the PRC. Further, it also provides bioanalytical services, which are offered throughout the drug discovery and development process both in the United States and China.